EA200970573A1 - Агенты, усиливающие действие амра-рецепторов - Google Patents

Агенты, усиливающие действие амра-рецепторов

Info

Publication number
EA200970573A1
EA200970573A1 EA200970573A EA200970573A EA200970573A1 EA 200970573 A1 EA200970573 A1 EA 200970573A1 EA 200970573 A EA200970573 A EA 200970573A EA 200970573 A EA200970573 A EA 200970573A EA 200970573 A1 EA200970573 A1 EA 200970573A1
Authority
EA
Eurasian Patent Office
Prior art keywords
action
ampa receptors
strengthening
agents
agents strengthening
Prior art date
Application number
EA200970573A
Other languages
English (en)
Other versions
EA015600B1 (ru
Inventor
Эстебан Домингес-Мансанарес
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200970573A1 publication Critical patent/EA200970573A1/ru
Publication of EA015600B1 publication Critical patent/EA015600B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к соединению, соответствующему формуле I, или фармацевтически приемлемой соли указанного соединения, которое можно применять для лечения состояний, связанных со снижением функции глутамата, например психиатрических и неврологических нарушений.
EA200970573A 2006-12-11 2007-12-06 Агенты, усиливающие действие амра-рецепторов EA015600B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06380319 2006-12-11
US88856207P 2007-02-07 2007-02-07
PCT/US2007/086567 WO2008073789A1 (en) 2006-12-11 2007-12-06 Ampa receptor potentiators

Publications (2)

Publication Number Publication Date
EA200970573A1 true EA200970573A1 (ru) 2009-10-30
EA015600B1 EA015600B1 (ru) 2011-10-31

Family

ID=39272878

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970573A EA015600B1 (ru) 2006-12-11 2007-12-06 Агенты, усиливающие действие амра-рецепторов

Country Status (10)

Country Link
US (1) US8097652B2 (ru)
EP (1) EP2102153A1 (ru)
JP (1) JP2010512339A (ru)
KR (1) KR20090082278A (ru)
CN (1) CN101541741A (ru)
AU (1) AU2007333247B2 (ru)
CA (1) CA2672462A1 (ru)
EA (1) EA015600B1 (ru)
MX (1) MX2009006243A (ru)
WO (1) WO2008073789A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2603513T3 (da) 2010-08-10 2020-06-15 Takeda Pharmaceuticals Co Heterocyklisk forbindelse og anvendelse deraf som AMPA-receptorpositiv allosterisk modulator
WO2012137982A2 (en) 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
WO2019120094A1 (zh) * 2017-12-21 2019-06-27 深圳市塔吉瑞生物医药有限公司 用于抑制激酶活性的芳基磷氧化物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
JP2003534316A (ja) * 2000-05-19 2003-11-18 イーライ・リリー・アンド・カンパニー スルホンアミド誘導体

Also Published As

Publication number Publication date
EP2102153A1 (en) 2009-09-23
US8097652B2 (en) 2012-01-17
EA015600B1 (ru) 2011-10-31
WO2008073789A1 (en) 2008-06-19
CA2672462A1 (en) 2008-06-19
CN101541741A (zh) 2009-09-23
AU2007333247B2 (en) 2012-06-07
MX2009006243A (es) 2009-08-12
US20100010090A1 (en) 2010-01-14
KR20090082278A (ko) 2009-07-29
AU2007333247A1 (en) 2008-06-19
JP2010512339A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
RS52780B (en) MEANS OF PREVENTION AND TREATMENT OF DISORDERS CONCERNING MODULATION OF RYR RECEPTORS
EA200601556A1 (ru) Тетрагидрохинолиноны и их применение в качестве антагонистов метаботропных глутаматных рецепторов
EA200801934A1 (ru) 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2
DE602005023197D1 (de) -muscarinrezeptors
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
EA200702470A1 (ru) Производные пиррола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
EA200800660A1 (ru) Тетрагидрохинолиноны и их применение в качестве модуляторов метаботропных глутаматных рецепторов
TW200744586A (en) Therapeutic compounds
MX2007014400A (es) Novedosos compuestos heterociclicos como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
EA200700909A1 (ru) Азаиндолкарбоксамиды
MX2007014444A (es) Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
GB0510143D0 (en) Novel compounds A1
EA200901160A1 (ru) Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
WO2006123244A3 (en) Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
EA201000319A1 (ru) Производные азациклилизохинолинона и изоиндолинона в качестве антагонистов гистаминовых рецепторов подтипа 3
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MX2009006359A (es) Derivados de aril sulfamida y metodos para su uso.
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU